Business ❯ Pharmaceutical Industry

Drug Development

Clinical Trials Market Competition Clinical Research Market Trends Regulatory Affairs Market Approval Market Access Market Launch Market Impact Regulatory Approval FDA Approval Novo Nordisk Market Regulation Market Analysis Weight Loss Drugs Partnerships Market Authorization Market Pricing Eli Lilly Lykos Therapeutics Psychedelic Drugs Pricing Strategies Market Potential Regulatory Challenges Research and Development GLP-1 Medications Regulatory Compliance FDA Approval Process Acquisitions Generic Drugs Market Strategy Biosimilar Drugs Cost Analysis Market Demand Orphan Drugs Licensing Agreements Clinical Studies Research Funding Weight-loss Drugs Gilead Sciences Generic Medications Collaborations Product Launch Collaboration Psychedelic Companies Market Expansion FDA Approvals Semaglutide Gene Therapy Corporate Ethics Investment in Healthcare Clinical Research Organizations Inflation Reduction Act Company Responses Weight-Loss Drugs Nirsevimab Market Dynamics Antibiotics Production Competition Market for Addiction Treatments Market Introduction Biopharmaceuticals Research Collaboration Biosimilar Launches Gene Therapies Karuna Therapeutics Mifepristone Ruling Antibody-Drug Conjugates Oncology Sales Investor Confidence Drug Pricing Drug Approval Leqembi Tirzepatide ALS Treatment Alzheimer's Drug Development Liver Disease Treatment Weight-Loss Drug Development Clinical Trials Support ALS Treatments Alzheimer's Disease Drug Safety Innovative Medicines AI Integration Patent Applications Vaccine Manufacturers Global Market Access Manufacturing Patient Charities Vaccine Approval Market Exclusivity Legal Issues Covid Drugs Novo Nordisk and Eli Lilly Cost Reduction Strategies Regulatory Approvals COVID-19 Drugs FDA Regulations Covid-19 Vaccines Operation Warp Speed

Lilly’s Foundayo Pill Significantly Improves Sleep Apnea in Late‑Stage Trials

Lilly plans a year‑end FDA filing that could widen non‑PAP treatment options for adults who are overweight or have obesity.

Stories older than 24h

Two High‑Profile Heart Trials Fail to Cut Events Despite Big Biomarker Drops

Lilly’s Retatrutide Outperforms Ozempic in Late‑Stage Diabetes Trial

Retatrutide Drives Record Weight Loss in Type 2 Diabetes, Company Moves Toward U.S. Filing

uniQure Shares Plummet After AMT-130 Misses Pre-Specified Statistical Goal

Lawsuits Over GLP‑1 Drugs Mount After Reports of Rare Sudden Vision Loss

Stanford’s 37,000‑Agent 'Virtual Biotech' Finds Trial‑Success Signal and Designs Lung‑Cancer Therapy

Definium’s LSD-Based Therapy Posts Third Positive Phase 3 Result in GAD

Novartis’ Pelacarsen Fails Phase 3 Outcome Trial

Novartis’ Del‑Desiran Misses Phase III and Triggers Large Share Selloff

Novartis' Pelacarsen Fails Phase 3 After Lowering Lp(a)

Novo Nordisk’s Semaglutide Eases Childhood Obesity as Heart-Drug Trials Are Halted

Ultragenyx Phase 3 Angelman Drug Fails to Show Benefit

FDA Expands Mounjaro Label to Include Cardiovascular Risk Reduction

FDA Approves Mounjaro to Lower Heart‑Attack and Stroke Risk in High‑Risk Type 2 Diabetes

Moderna and Merck Report Positive Phase 3 Result for Personalized mRNA Melanoma Vaccine

FDA Grants Accelerated Approval to Genglycos for Glycogen Storage Disease Type Ia

AstraZeneca Stops Phase III Volrustomig Lung Cancer Trial

UK Approves Lilly’s Oral GLP‑1 Pill Foundayo

AbCellera’s Menopause Antibody Hits Phase 2 Goals